Actinium Pharmaceuticals Stock News

-  Late-breaker presentation at 5:00 PM EST on Saturday, February 18, 2023, to feature Iomab-B SIERRA Pivotal Trial results -  Investor call at 6:00 PM EST on Saturday, February 18, 2023, to highlig

Actinium Pharmaceuticals is delivering the goods on a deep pipeline of therapeutics. It has deepened its bench with experienced operators.

Shares of Actinium Pharmaceuticals Inc. ATNM, +24.20% were up 22.8% in trading on Monday after the company met the primary endpoint in a Phase 3 clinical trial for its investigational treatment for re

Actinium Pharmaceuticals (NYSEMKT: ATNM ) stock is gaining on Monday after posting positive results from a Phase 3 clinical trial. The point of this clinical trial was to determine the effectiveness o

Riding two powerful franchises (Iomab and Actimab), Actinium Pharmaceuticals is brewing a deep pipeline of therapeutics for multiple indications. There is also AWE Technology that is developed in coll

Actinium (ATNM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the ro

Actinium Pharmaceuticals, Inc.'s results from the phase 3 SIERRA trial, using Iomab-B as a preconditioning agent in patients over the age of 55 with active relapsed/refractory AML are expected Q4 of 2

Here is how Alkermes (ALKS) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.

Actinium (ATNM) out-licenses exclusive rights to Iomab-B, an antibody radiation conjugate for facilitating bone-marrow transplant, to Immedica in Europe, the Middle East and North African countries.

Actinium (ATNM) out-licenses exclusive rights to Iomab-B, an antibody radiation conjugate for facilitating bone-marrow transplant, to Immedica in Europe, the Middle East and North African countries.

Biotech stocks are up today amid an influx of positive news. Here's what investors need to know as these small companies skyrocket.

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Aeglea Shares Additional Phase 3 Data In Inherited Metabolic Disease Aeglea BioTherapeutics Inc (NAS

Actinium Pharmaceuticals Inc (AMEX:ATNM) shares are trading higher Tuesday morning after the company announced it entered into a license and supply agreement with Immedica Pharma for Iomab-B.  Actin

Actinium Pharmaceuticals Inc. (ATNM) shares closed today at 0.9% above its 52 week low of $5.65, giving the company a market cap of $125M. The stock is currently down 5.2% year-to-date, down 32.3% over the past 12 months, and down 82.4% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 0.7%. Trading Activity Trading volume this week was 23.2% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -35.2% The company's stock price performance over the past 12 months beats the peer average by -29.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.